FGD4 (Frabin) Overexpression in Pancreatic Neuroendocrine Neoplasms

Mohammad Shahid1, Tarra B George1, James Saller1

  • 1From the Departments of Anatomic Pathology.

Pancreas
|November 6, 2019
PubMed
Abstract

Insights

Frabin is overexpressed in pancreatic neuroendocrine tumors (PNETs) and pancreatic neuroendocrine carcinomas (PECA). This finding suggests Frabin as a novel molecular alteration in these PNETs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The pathogenesis of pancreatic neuroendocrine tumors (PNETs) remains incompletely understood.
  • Frabin, a guanine nucleotide exchange factor, influences actin cytoskeleton dynamics crucial for cell migration, morphogenesis, polarization, and division.

Purpose of the Study:

  • To investigate Frabin as a potential molecular alteration in PNETs.
  • To assess Frabin expression in PNETs and pancreatic neuroendocrine carcinomas (PECA).

Main Methods:

  • Immunohistochemistry and tissue microarray were used to evaluate Frabin expression in 29 PNET/PECA samples.
  • Frabin immunostain was scored using the Allred system and correlated with tumor grade and stage.
  • Statistical analysis included Spearman correlation coefficient and P values.

Main Results:

  • Frabin was expressed in 82.7% (24/29) of the studied PNETs/PECAs, with cytoplasmic localization.
  • A significant positive correlation was observed between Frabin immunohistochemistry score and tumor grade (ρ = 0.47, P = 0.01).
  • No significant correlation was found between Frabin expression and tumor stage (P = 0.91).

Conclusions:

  • Frabin overexpression represents a novel molecular alteration in PNETs and PECAs.
  • Frabin expression correlates with the grade of pancreatic neuroendocrine tumors.

Related Concept Videos